News

Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. The three Phase 1 studies were

The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The

Dexamethasone is being developed for administration as a one-time, bioresorbable intracanalicular plug for drug release to the ocular surface for up 30 days. A total of 40 patients

Nefecon is a new oral modified-release capsule of the corticosteroid, budesonide, being developed to treat patients with IgA nephropathy (IgAN) at risk of developing end-stage renal disease (ESRD),

Currently, the company has completed patient enrollment in a Phase III trial and it expects induction response rate data to be available in the second quarter of 2015.

Recently, Spiriva Respimat was approved by the US Food and Drug Administration (FDA) for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)

Offering a new treatment option for psoriasis patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A and inhibit interaction with the

The Phase II clinical trial is currently underway in nine countries, and will involve around 50 sites. Primary objective of the trial is to determine the most effective

"We have tested over 1,500 chemotherapeutic agents in our head and neck cancer cell lines and COTI-2 is the most active drug that we have ever seen in